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Abstract
Vaccines based on peptide mimics (mimotopes) of conformational tumor antigen epitopes have been investigated for a
variety of human tumors including breast cancer, tumors expressing the carcinoembryonic antigen, B cell lymphoma,
neuroblastoma, and melanoma. In our previous work, we designed a vaccine based on a mimotope of the high molecular
weight-melanoma associated antigen (HMW-MAA) that elicited HMW-MAA-specific antibodies (Abs) with anti-tumor activity
in vitro and in vivo. In this study, we aimed to identify mimotopes of additional distinct HMW-MAA epitopes, since they
could be used to construct a polymimotope melanoma vaccine. For this purpose, random peptide phage libraries were
screened with the anti-HMW-MAA monoclonal antibodies (mAbs) VT80.12 and VF1-TP43 yielding one peptide ligand for
each mAb. Both peptides inhibited the binding of the corresponding mAb to the HMW-MAA. Furthermore, when coupled
to the carrier protein keyhole limpet hemocyanin (KLH), both HMW-MAA mimotopes elicited peptide-specific Abs in rabbits
or BALB/c mice, but only the mimotope isolated with the mAb VT80.12 elicited HMW-MAA-specific Abs and only in mice.
However, the latter Abs had no detectable effect on HMW-MAA expressing human melanoma cells in vitro. These results
describe limitations related to the phage display technique and emphasize the need to characterize the functional
properties of the mAb utilized to isolate mimotopes of the corresponding epitopes.
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Introduction
For at least two decades, the high molecular weight-melanoma
associated antigen (HMW-MAA) has been the focus of several
studies to implement effective immunotherapy for melanoma.
Originally identified with murine monoclonal antibodies (mAbs) on
the surface of human melanoma cell lines, HMW-MAA has been
found to be expressed in at least 80% of primary and metastatic
melanomas and more recently, in several other tumors as well as on
cancer stem cells [1,2]. However, HMW-MAA expression is not
restricted to transformed cells, as it has been found on various cells
of normal tissues including melanocytes, hair follicles and basal cells
of the epidermis as well as endothelial cells, chondrocytes and
pericytes [1]. Its expression on both activated and resting pericytes
in tumor vessels has suggested that HMW-MAA is critical to tumor
angiogenesis [2]. Furthermore, HMW-MAA is known to contribute
to the malignant phenotype of melanoma by activating several
signaling cascades (e.g. Rho GTPases, p130
cas, FAK) that are
involved in adhesion, migration and invasion of melanoma cells [3].
The possibility that HMW-MAA represents a useful target to
implement immunotherapy of melanoma has been initially
suggested by the association between development of HMW-
MAA-specific antibodies (Abs) and statistically significant survival
prolongation in patients with advanced melanoma immunized with
a mouse anti-idiotypic mAb which mimics a HMW-MAA epitope
[4,5]. This possibility has been further supported by the results of
several preclinical studies which have targeted HMW-MAA with
Ab- and T cell-based immunotherapeutic strategies. Recently,
Maciag et al. generated a Listeria monocytogenes (Lm)-based vaccine
against HMW-MAA [6]. Immunization of C57BL/6 mice bearing
B16F10-HMW-MAA melanomas induced HMW-MAA-specific
CD8
+ and CD4
+ T cells that were equally required for tumor
inhibition, as in vivo depletion of each of these cells resulted in
uncontrolledtumor growth [6]. Noteworthy,inthisstudyfor thefirst
timea syngeneic melanoma mouse model for HMW-MAA was used
and novel information on the contribution of T cells to the
therapeuticefficacyofHMW-MAA-specificimmunitywasprovided.
In contrast, we have emphasized the induction of HMW-MAA-
specific humoral immunity by using mimotopes as immunogens.
Mimotopes are small peptides that mimic conformational B cell
defined-epitopes of antigens and can be selected by screening
random peptide phage libraries with a mAb of interest. As
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sequence with the original antigen, they represent useful antigen
surrogates to overcome immunotolerance to self-antigens [7–10].
Regarding melanoma, this is of particular interest as most
melanoma associated antigens including the HMW-MAA are
self-antigens [1,11].
In previous studies, we have identified a linear HMW-MAA
mimotope (225D9.2+) which mimics the epitope recognized by the
HMW-MAA-specific mAb 225.28S. Immunization with this
mimotope coupled to tetanus toxoid induced HMW-MAA-specific
Absinrabbits that inhibited melanomacell proliferationinvitro [12].
Passive administration of these Abs in a xenogeneic melanoma
SCID mouse model inhibited tumor growth up to 40% and 62% in
a therapeutic and prophylactic setting, respectively [13].
As epitope loss is commonly found in melanoma cells [14] and
studies have shown that induction of antibodies against multiple
epitopes of a breast cancer tumor antigen increased tumor growth
inhibition [15,16], efficacy of a melanoma vaccine might be
improved by vaccination with several peptides. In this regard, we
report the selection of mimotopes of additional HMW-MAA
epitopes which are distinct from that defined by the mAb 225.28S
and discuss limitations related to mimotope vaccines regarding
their immunogenicity and antigenicity.
Materials and Methods
Ethics statement
Mice were treated according to European Union Rules of
Animal Care and all experiments were approved by the Animal
Experimentation Committee of the Medical University of Vienna
and the Austrian Ministry of Science (permission 66.009/152-II/
10b/2009).
Monoclonal anti-HMW-MAA Abs
The mAbs VT80.12, VF1-TP43, and TP61.5 were developed
and characterized as described elsewhere [17–19].
Biotinylation of Abs (mAbs, rabbit IgG)
NHS-LC-Biotin (Pierce, Rockford, IL, USA) was diluted in
dimethylformamide at a concentration of 40 mg/ml. Five
microliters of this solution was added to 1 mg/ml mAb or rabbit
IgG in PBS and incubated for 45 min at room temperature (RT).
Excess NHS-LC-Biotin was removed by dialysis against PBS.
Cell lines
The human melanoma cell line 518A2 [20] which expresses
high levels of HMW-MAA and M14 [21], a human melanoma cell
line with no detectable expression of HMW-MAA, were
maintained in RPMI 1640 medium (Lonza, Verviers, Belgium)
supplemented with 10% (v/v) FCS and 1% (v/v) antibiotic-
antimycotic mix (both from Gibco, Paisley, UK). Both cell lines
were cultured in a humidified atmosphere containing 5% CO2
and 95% ambient air at 37uC.
Microsomal preparations
Microsomal preparations were performed using ,5610
7 cells
according to the protocol described elsewhere [22]. Protein
concentration was determined using a bicinchoninic acid (BCA)
protein assay (Pierce).
Phage display, affinity selection and sequence analysis
Peptide ligands for the mAb VT80.12 were selected from a
pVIII-15mer phage display peptide library [23]. Therefore, the
mAb VT80.12 was immobilized and incubated with ,10
10
phages. Phages displaying peptides that bound to the mAb
VT80.12 were eluted and amplified in E. coli TG1.
Peptide ligands for the mAb VF1-TP43 were selected using the
Ph.D.-12
TM Phage Display Peptide Library, a pIII-12mer library,
purchased from New England Biolabs (Ipswich, MA, USA).
Biopanning was performed following the manufacturer’s instructions.
After three rounds of selection, single phage clones that bound
to the respective mAb and not to the isotype-matched control
mAb in phage ELISA were subsequently subjected for DNA
sequencing. Obtained sequences were not deposited in GenBank.
Synthesis of peptides
The peptides GRQYYEGRKPDYRAAC (15/3/6) and
NYQDLQRTHFKSGPGPGC (43.12p3) were synthesized using
F-moc strategy by piCHEM (Graz, Austria). The purity of the
peptides was ,95%, as assessed by HPLC.
ELISA inhibition assay
MaxiSorp immunoplates (Nunc, Rosklide, Denmark) were
coated overnight (o/n) at 4uC with mAb T61.5 (4 mg/ml in
50 mM Na-carbonate buffer, pH 9.6). Biotinylated mAb (10 ng)
was incubated o/n at 4uC with increasing concentrations (10, 50,
100, and 500 mg/ml) of synthetic peptides in TBST (0.5% (v/v)
Tween-20) containing 1% (w/v) BSA. After blocking with TBST/
3% (w/v) milk powder, plates were incubated for 3 h at RT with
microsomal preparations (100 mg/ml in TBST/1% BSA) to catch
HMW-MAA. After washing, the mAb preincubated with peptides
was added to the plate and incubation was continued for an
additional hour at RT. Bound biotinylated mAb was detected
using alkaline phosphatase (AP)-conjugated streptavidin (GE
Healthcare, Little Chalfont, UK), followed by the addition of p-
nitrophenylphosphate (Sigma). Absorbance was measured at
405 nm. Percentage of inhibition was calculated as follows:
1002(OD (inhibited)/OD (uninhibited)6100).
Conjugation of peptides
Peptides were coupled to the carrier protein keyhole limpet
hemocyanin (KLH; Sigma, St. Louis, MO, USA) or bovine serum
albumin (BSA; Pierce) using the heterobifunctional crosslinker
reagent m-maleimidobenzoyl-N-hydroxysuccinimide (MBS; Pierce)
as described previously [12]. Conjugation of the peptides to the
carrier proteins was verified in a dot blot assay as follows. Peptide
conjugates were dotted onto nitrocellulose (NC) membrane (What-
man, Dassel, Germany). After blocking with PBST (0.5% Tween-
20) containing 3% milk powder, NC strips were incubated with
biotinylated mAb, followed by AP-conjugated streptavidin (GE
Healthcare). Color development was done with 5-bromo-4-chloro-
3-indolyl phosphate/nitroblue tetrazolium.
Immunizations
Female New Zealand white rabbits (2 groups, n=1; 13–17
weeks old) were immunized s.c. at the Charles River Laboratories
(Kisslegg, Germany) on day 1, 29, and 43 with 200 mg peptide-
KLH conjugate or KLH alone adsorbed to CFA (for priming) and
to IFA (for boosting). Serum samples were harvested before
treatment (preimmune serum), on day 11 and 39. Rabbits were
sacrificed on day 57.
Female BALB/c mice (4 groups, n=3; 6–8 weeks old; Charles
River Laboratories, Sulzfeld, Germany) were immunized i.p. on
day 1, 15, and 29 each with 15 mg of the peptide-KLH conjugates
or KLH alone adsorbed to aluminum hydroxide (alum; Serva,
Heidelberg, Germany) in a total volume of 150 ml PBS solution.
HMW-MAA Mimotopes
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samples were taken on day 0 (preimmune serum), 22 and 41, and
mice were sacrificed on day 48.
Purification of rabbit or mouse IgG Abs
Total IgG were purified from sera of the immunized rabbits
according to the protocol described elsewhere [12].
Mouse IgG were purified from serum samples taken after the
third immunization or after sacrifice of mice. Therefore, sera from
the three mice of each group were pooled and diluted with an
equal volume of binding buffer (20 mM Na-phosphate, pH 7.0).
The HiTrap Protein G HP column (GE Healthcare) was
equilibrated with binding buffer and the sample applied. Bound
IgG were eluted with 100 mM glycine-HCl, pH 2.7 and
neutralized by the addition of 1 M Tris-HCl, pH 9.0.
Purification of rabbit and mouse IgG was monitored using
nonreducing 8% SDS-PAGE. Protein concentration was deter-
mined by a BCA protein assay (Pierce).
Peptide-specific Ab response
MaxiSorp immunoplates (Nunc) were coated o/n at 4uC with
10 mg/ml peptide-BSA conjugates or KLH or BSA in 50 mM Na-
carbonate buffer, pH 9.6. Nonspecific binding sites were blocked
with TBST/3% milk powder. Purified rabbit IgG (0.05–10 mg/ml
in TBST/0.5% BSA) or mouse sera (diluted 1:1000 in TBST/
0.5% BSA) were added to antigen-coated plates and incubated for
2 h at RT. After washing, bound Abs were detected using AP-
conjugated swine anti-rabbit IgG (diluted 1:1000 in TBST/0.5%
BSA; Dako, Glostrup, Denmark) or AP-conjugated rabbit anti-
mouse IgG+IgM (diluted 1:5000 in TBST/0.5% BSA; Jackson
ImmunoResearch, West Grove, PA, USA). Color development
was performed as described for the ELISA inhibition assay.
HMW-MAA-specific Ab response
ELISA protocol. For the detection of the HMW-MAA-
specific Ab response, HMW-MAA was purified from microsomal
preparations as described for the ELISA inhibition assay. After
blocking and catching, plates were incubated for 2 h at RT with
increasing concentrations (12.5, 50, and 200 mg/ml) of purified
rabbit IgG diluted in TBST/1% BSA. Bound IgG was detected as
described for the peptide-specific Ab response.
FACS protocol. Flow cytometric analysis of melanoma cells
stained with sera from immunized mice or purified IgG from
immunized rabbits was performed as previously described [24].
Briefly, 5610
5 cells were incubated for 1 h on ice with a 1:10
dilution of pooled mouse sera for each group or 100 mg purified
rabbit IgG in 100 ml PBS/1% BSA. MAb VT80.12 (1 mg) served
as positive control staining of HMW-MAA. Cells were then
washed twice with PBS/0.5% BSA and incubated for an
additional 30 min on ice with FITC-labeled goat anti-mouse
IgG or FITC-labeled goat anti-rabbit IgG (both diluted 1:2000 in
PBS/1% BSA; AbD Serotec, Du ¨sseldorf, Germany). After
washing, cells were resuspended in PBS/0.5% BSA and 20,000
gated events were analyzed by flow cytometry on a BD
FACScanto using BD FACSDiva software (BD Biosciences,
Franklin Lakes, NJ, USA). Histogram overlays were done
applying FlowJo software (Tree Star, Ashland, OR, USA).
Immunohistochemical (IHC) staining. IHC staining of solid
518A2 tumors established in C.B.17 SCID/SCID mice was
performed as described by Wagner et al. [13]. Briefly, tumor
sections were incubated with either blocking buffer (negative control),
biotinylated mAb VT80.12 (30 mg/ml; positive control) or
biotinylated IgG (100 mg/ml) purified from rabbits either
immunized with 15/3/6-KLH conjugate or KLH. After washing
with TBST, slides were incubated with StreptABComplex/HRP
(Dako) for 30 min. Specific Ab binding was visualized by a DAB
chromogen solution (Dako) following hematoxylin counterstaining.
Stained slides were viewed by an Olympus Vanox AHBT3
microscope and photographed with a Zeiss AxioCam MRc5 camera.
Inhibition of tumor cell growth in vitro
Tumor cells were seeded in 96-well tissue culture plates (Costar;
Corning, NY,USA) at 1500 cells/well. Cells were allowed to adhere
o/n at 37uC. IgG purified from mice either immunized with 15/3/
6-KLH conjugate or KLH were added at increasing concentrations
(0.01, 0.1, and 1 mg/ml) and incubation was continued for
additional 72 h at 37uC. Cells were pulsed with 0.5 mCi of
[methyl-
3H]thymidine/well (GE Healthcare) for another 6 h at
37uC and then harvested. Incorporated [
3H]thymidine was
measured by a Wallac MicroBeta TriLux 1450 counter (PerkinEl-
mer, Waltham, MA, USA). Percentage of inhibition of proliferation
was calculated by comparing cpm values of treated cells with those
of untreated cells, which were set at 100%.
Results
Identification of peptide ligands
Biopanning of the mAb VT80.12 was performed with a linear
pVIII-15mer phage display peptide library. After three rounds of
Figure 1. Inhibition of mAb binding to HMW-MAA by synthetic
peptides. Microtiter plates were coated with mAb TP61.5 and
incubated with microsomal preparation of 518A2 melanoma cells to
catch HMW-MAA. Biotinylated mAbs were preincubated with increasing
concentrations of synthetic peptides, followed by incubation with
HMW-MAA. (A) Biotinylated mAb VT80.12 was preincubated with
peptide 15/3/6 (N) or an irrelevant control peptide (m). (B) Biotinylated
mAb VF1-TP43 was preincubated with peptide 43.12p3 (&) as well as
the control peptide (m). Binding of biotinylated mAbs was measured
using an AP-conjugated streptavidin. Percentage of inhibition was
calculated as follows: 1002(OD (inhibited)/OD (uninhibited)6100).
doi:10.1371/journal.pone.0019383.g001
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VT80.12 was increased from 1610
5 CFU/ml in the 1
st round to
1610
9 CFU/ml in the 3
rd round. Twenty individual phage clones
of each the 2
nd and 3
rd round were tested for their ligand
specificity in phage ELISA. Among these, eighteen (2
nd round) and
nineteen (3
rd round) phage clones specifically bound to the mAb
VT80.12. DNA sequencing of these 37 phage clones yielded one
peptide sequence GRQYYEGRKPDYRAA (‘‘15/3/6’’). The
peptide 15/3/6 was chemically synthesized with an additional
C-terminal cysteine residue for conjugation purposes. In ELISA
inhibition experiments, this peptide inhibited the binding of the
mAb VT80.12 to the HMW-MAA up to 93% (Figure 1A).
Biopanning of the mAb VF1-TP43 was performed with a linear
pIII-12mer phage display peptide library. Three rounds of
selection yielded an increase of phage titer from 1610
5 pfu/ml
(1
st round) to 3610
9 pfu/ml (3
rd round). Among 30 tested phage
clones, 20 were specifically recognized by the mAb VF1-TP43 in
phage ELISA. DNA sequencing yielded one peptide sequence
NYQDLQRTHFKS (‘‘43.12p3’’). The peptide 43.12p3 was
synthesized with a GPGPG-linker to improve presentation on
the surface of the carrier protein and an additional C-terminal
cysteine residue. In subsequent inhibition experiments, this
peptide inhibited the binding of the mAb VF1-TP43 to the
HMW-MAA up to 100% (Figure 1B).
Peptide-specific Ab response in rabbits
The peptide 15/3/6 was coupled to KLH or BSA as carrier
protein. Conjugation to the carrier protein was confirmed in a dot
blot assay (data not shown). New Zealand white rabbits were
immunized with the 15/3/6-KLH conjugate or the carrier protein
KLH alone. After three immunizations, IgG were purified using a
HiTrap protein A HP column. Twenty milliliters of serum yielded
,20 mg of IgG Abs. The purity was greater than 95% as
confirmed by SDS-PAGE (data not shown). Peptide-specific Abs
were determined by ELISA after incubation of coated peptide-
BSA conjugate, BSA or KLH with purified IgG Abs. BSA-
conjugates were used to ensure detection of peptide-specific IgG.
Both, 15/3/6- and KLH-specific Abs were already detectable at a
concentration of 0.05 mg/ml and their levels increased in a dose-
dependent manner (Figure 2). Abs purified from the KLH-
immunized rabbit did not bind to the peptide. No Abs directed
against BSA could be determined.
HMW-MAA-specific Ab response in rabbits
HMW-MAA specificity of purified rabbit IgG was determined
in ELISA by testing their binding ability to HMW-MAA purified
from microsomal preparations of 518A2 cells. 15/3/6-KLH
conjugate induced Abs bound to the HMW-MAA, but also when
the HMW-MAA catching mAb was incubated with microsomal
preparations of M14 cells (HMW-MAA
neg), binding of these Abs
was detected (Figure 2). The same results were observed for the
KLH-induced Abs (Figure 2). Even when the HMW-MAA
catching mAb was directly incubated with the purified rabbit
IgG and subsequently detected with AP-conjugated swine anti-
rabbit IgG, high background levels were measured (data not
shown).
In a second approach, HMW-MAA specificity of rabbit IgG
was investigated by FACS analysis. The HMW-MAA positive
Figure 2. Antigen- and HMW-MAA-specific immune response of immunized rabbits. Left panel: Microtiter plates were coated with 15/3/
6-BSA conjugate, KLH or BSA and incubated with increasing concentrations of purified rabbit IgG from immunizations with 15/3/6-KLH conjugate or
KLH to detect peptide- and KLH-specific Abs. Right panel: Microtiter plates were coated with mAb TP61.5 and incubated with microsomal
preparations of the melanoma cell lines 518A2 or M14. Purified rabbit IgG were analyzed by administration of increasing Ab concentrations.
doi:10.1371/journal.pone.0019383.g002
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pos) or the HMW-
MAA negative human melanoma cell line M14 (HMW-MAA
neg)
were incubated with each 100 mg purified rabbit IgG and detected
with a FITC-labeled goat anti-rabbit IgG. As expected, the mAb
VT80.12 specifically bound to the HMW-MAA
pos, but not to the
HMW-MAA
neg cells. However, HMW-MAA specificity of the 15/
3/6-KLH conjugate induced Abs could not be observed, as Abs
induced by KLH showed a similar staining pattern to HMW-
MAA
pos as well as to HMW-MAA
neg cells (Figure 3A).
In a third approach, we used solid 518A2 tumors established in
C.B.17 SCID/SCID mice [13] to detect HMW-MAA-reactive
rabbit Abs by IHC. Whereas staining of melanoma cells was
observed with the biotinylated mAb VT80.12, none was observed
with either an isotype-matched control mAb (data not shown) or
PBS buffer. Also in this setup, we detected a background staining
of anti-KLH Abs on 518A2 tumor tissue that was comparable to
the staining of the anti-15/3/6-KLH Abs (Figure 3B).
Peptide-specific Ab response in BALB/c mice
The peptides 15/3/6 or 43.12p3 were coupled each to KLH or
BSA. Female BALB/c mice were immunized with 15 mg of the
peptide-KLH conjugates, KLH or were sham-treated with PBS
buffered alum. Serum samples of each group were tested for the
presence of peptide-specific Abs in ELISA. Peptide specificity was
Figure 3. HMW-MAA-specific Ab response determined by FACS and IHC. (A) The human melanoma cell lines 518A2 and M14 were each
incubated with 1 mg mAb VT80.12 (as positive control to detect HMW-MAA) or 100 mg purified rabbit IgG from immunizations with 15/3/6-KLH
conjugate or KLH. Bound IgG were detected with FITC-labeled goat anti-mouse IgG or FITC-labeled goat anti-rabbit IgG. Histogram overlays show
unstained (white) vs. stained cells (grey). (B) IHC on 518A2 tumor tissues of C.B.17 SCID/SCID mice [13]. HMW-MAA staining was done with PBS buffer
(negative control), mAb VT80.12 (positive control), and biotinylated IgG purified from rabbits immunized with 15/3/6-KLH conjugate (anti-15/3/6)o r
KLH (anti-KLH). Bound Abs were detected with StrepAB/HRP and visualized by DAB-chromogen solution and subsequent hematoxylin
counterstaining.
doi:10.1371/journal.pone.0019383.g003
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conjugate, as they bound to the corresponding peptide-BSA
conjugates (Figure 4). As expected, KLH-specific Abs were
detected in the KLH-group (Figure 4) as well as in the groups
immunized with the peptide-KLH conjugates (data not shown).
No peptide- (15/3/6 or 43.12p3), KLH- or BSA-specific Abs were
detected in the sera of sham-treated mice (data not shown).
HMW-MAA-specific Ab response in BALB/c mice
Preimmune serum samples or serum samples after the third
immunization of individual mice were pooled for each group.
Serum pools were diluted 1:10 and incubated with HMW-MAA
pos
or HMW-MAA
neg cells. Bound IgG were detected with a FITC-
labeled goat anti-mouse IgG by FACS analysis. No staining was
detected of HMW-MAA
pos or HMW-MAA
neg melanoma cells by
mouse preimmune serum pools (data not shown). The 15/3/6-
KLH conjugate induced HMW-MAA-specific Abs, whereas the
43.12p3-KLH conjugate did not (Figure 5). KLH-induced Abs
showed negligible background staining on HMW-MAA
pos as well
as HMW-MAA
neg cells.
Inhibition of tumor cell growth
The effect of anti-15/3/6-KLH Abs on tumor growth in vitro
was determined by a [
3H]thymidine proliferation assay. HMW-
MAA
pos or HMW-MAA
neg cells were incubated with increasing
concentrations of purified mouse IgG. Upon treatment with anti-
15/3/6 Abs, proliferation of HMW-MAA
pos cells was inhibited to
a maximum of ,17% (Figure 6). Almost identical results were
obtained, when either HMW-MAA
pos cells or HMW-MAA
neg
cells were treated with anti-KLH Abs.
Discussion
In this study we aimed to select two mimotopes defined by the
HMW-MAA-specific mAbs VT80.12 and VF1-TP43 that should
serve together with our previously described 225D9.2+ mimotope
[12,13] as components of a polymimotope vaccine against
melanoma.
We therefore screened two linear phage display peptide libraries
(pVIII-15mer with mAb VT80.12, pIII-12mer with mAb VF1-
TP43) yielding one peptide ligand for each mAb. Both peptides
(15/3/6: ligand to VT80.12; 43.12p3: ligand to VF1-TP43)
inhibited binding of the respective mAb to the HMW-MAA up to
100%, thereby proofing epitope mimicry and their definition as
mimotopes. Upon immunization of either rabbits or BALB/c
mice, each mimotope coupled to the carrier protein KLH
Figure 4. Antigen-specific immune response of immunized
BALB/c mice. Serum samples from day 0 (preimmune serum; white
bars), day 22 (grey bars), and day 41 (black bars) were tested in ELISA.
The mean value of the individual responses of each group is shown and
standard deviations are indicated by error bars. Peptide specificity of
sera from mice either immunized with 15/3/6- or 43.12p3-KLH
conjugate was assessed using the respective peptide-BSA conjugates.
Sera from KLH immunized mice were tested for specificity to KLH.
doi:10.1371/journal.pone.0019383.g004
Figure 5. HMW-MAA-specific immune response of immunized BALB/c mice. Human melanoma cell lines 518A2 and M14 were either
incubated with 1 mg mAb VT80.12 (as positive control) or a 1:10 dilution of pooled mouse sera of each group. Bound IgG were detected with FITC-
labeled goat anti-mouse IgG. Histogram overlays show unstained (white) and stained cells (grey).
doi:10.1371/journal.pone.0019383.g005
HMW-MAA Mimotopes
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Abs. However, only the 15/3/6-KLH conjugate induced HMW-
MAA-specific Abs in BALB/c mice, but these Abs failed to inhibit
tumor cell proliferation in vitro.
Epitope mimicry to HMW-MAA was confirmed for both
peptides 15/3/6 and 43.12p3 in ELISA inhibition experiments
(Figure 1). An important issue of this study was the applied animal
model in the context of the carrier protein used for vaccination.
Initially, immunization experiments were performed in rabbits as
high amounts of antibodies can be obtained from the blood for
subsequent in vitro tests. Although mimotope-specific Abs were
induced for the tested mimotope, these showed no HMW-MAA
specificity in ELISA experiments (Figure 2). Instead, we observed a
highbackground stainingofKLH-specific AbsontheHMW-MAA-
positive or -negative cell lysate, as well as on the HMW-MAA
catching mAb. Similarly, FACS staining (Figure 3A) as well as IHC
(Figure 3B) failed to confirm HMW-MAA-specific Abs. Immuni-
zations were then repeated in BALB/c mice to assess whether the
results from the rabbit immunizations were attributed to the carrier
protein KLH or the applied animal model. Using this model, FACS
analysis confirmed HMW-MAA specificity of mimotope-induced
Abs (Figure 5), indicating that the undesired binding of rabbit anti-
KLH Abs was likely attributed to the rabbit Abs and not to the
carrier protein KLH. However, we cannot exclude a possible
contribution of the used adjuvants (CFA/IFA in rabbits vs. alum in
BALB/c mice) to the unspecific binding of rabbit anti-KLH Abs, as
adjuvants are known to differentially deliver antigen and activate
the immune system [25]. We therefore conclude that the choice of
carrier protein has an impact on the outcome of vaccination and
might depend on the used immunization model.
Although the 43.12p3-KLH conjugate induced mimotope-
specific mouse Abs, these failed to cross-react with the natural
antigen HMW-MAA (Figure 5), indicating that immunogenicity of
mimotopes does not necessarily correlate with their specificity. The
discrepancy between epitope specificity of an anti-HMW-MAA
mAb and epitope specificity of HMW-MAA mimotope-induced
Abs is best described by previous studies of Wagner et al. [12] and
Hafner et al. [26]. Both studies deal with the identification of distinct
HMW-MAA mimotopes which were defined by the same mAb
(225.28S) and coupled to the same carrier protein (tetanus toxoid,
TT) for subsequent immunization experiments in rabbits. Using the
identical immunization protocol, a HMW-MAA-specific Ab
response was only obtained upon immunization with the mimo-
tope-TT conjugate described by Wagner et al. [12]. These findings
clearly indicate that – despite confirmed affinity selections as well as
analog immunization protocols – not every mimotope truly mimics
the relevant epitope of the original antigen. On the one hand,
limitations might originate during affinity selection as phage
displaying peptides may bind to residues of the mAb that are not
part of the paratope. Although such peptides might inhibit the
bindingoftheir defined mAbtotheoriginal epitope,thesewill fail to
induce a specific immune response to the original antigen. In
addition, B cell epitopes are known to be conformational in nature
[27]. Hence, it is possible that mAbs recognize certain conforma-
tions of epitopes which are not displayed in the same structural
context by the natural antigen. The above-described limitations
probably outline the major pitfall of the phage display technique
that complicates the selection of ‘‘true’’ mimotopes, solely based on
their binding characteristics to mAbs. On the other hand, it is to
state that immunization with mimotopes does not guarantee the
induction of Abs that display the appropriate paratope to the
natural antigen,emphasizing alsoa possiblecontributionofthe used
animal model to the outcome of mimotope vaccination. This might
be of particular relevance for other investigators who apply
mimotopes for vaccination strategies.
Immunization of BALB/c mice with the 15/3/6 mimotope
conjugate resulted in the induction of mimotope- and HMW-MAA-
specific Abs (Figure 4 and 5). However, these Abs showed no anti-
tumor activity in in vitro proliferation assays (Figure 6). Importantly,
the mAb VT80.12 itself does not inhibit tumor cell proliferation
neither directly nor indirectly by mediating ADCC or CDC [28]. We
therefore have to question whether anti-tumor activity in vivo of the
mimotope defining mAb should be a prerequisite to induce
antibodies with tumor inhibiting properties. As a matter of fact,
certain mAbs (e.g. Rituximab [29–32], Cetuximab [33,34], Trastu-
zumab [10,35]), which are currently applied for cancer therapies and
have successfully served as sources to generate mimotope vaccines
with anti-tumor activity invitro, fulfill thisrequirement, even though in
vivo results for these mimotope vaccines are not yet available. As
reported by Hafner et al., passive administration of the anti-HMW-
MAA mAb 225.28S significantly reduced tumor volume in a human
melanoma xenotransplant SCID mouse model, although this mAb
hadnoeffectonhumanmelanomacellsinvitro[ 3 6 ] .T h i ssu p p o r t st h e
hypothesis of using mAbs with in vivo rather than in vitro anti-tumor
activity for the selection of mimotopes.
To date, only one mimotope-based vaccine targeting the
HMW-MAA has demonstrated anti-tumor activity in vitro [12]
and in vivo [13]. The identification of additional HMW-MAA
mimotopes as components of an effective polymimotope vaccine
might depend on the in vivo anti-tumor activity of the selecting
mAbs per se but also on the used animal model as well as on the
paratope conformation of the mimotope-induced Abs. In addition,
we suggest that the efficacy of every mimotope-based vaccine
should be evaluated in an animal model by active immunization.
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Figure 6. Inhibition of melanoma cell proliferation in vitro.
[
3H]thymidine proliferation assay demonstrating effects of purified
mouse IgG on HMW-MAA expressing melanoma cells. 518A2 or M14
cells were incubated with increasing concentrations of purified IgG
from mice immunized with 15/3/6-KLH conjugate or KLH for 72 h and
pulsed with [
3H]thymidine. Data are presented as percentage of
inhibition of proliferation compared to untreated cells. Percentage of
inhibition was calculated as follows: 1002(cpm (treated)/cpm (untreat-
ed)6100). Values represent the mean of three independent experi-
ments.
doi:10.1371/journal.pone.0019383.g006
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